Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Al Ali, Najla [1 ]
Sallman, David [1 ]
Chan, Onyee [1 ]
Padron, Eric [1 ]
Sweet, Kendra [1 ]
Kuykendall, Andrew [1 ]
Lancet, Jeffrey [1 ]
Komrokji, Rami [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
MDS; azacitidine; venetoclax;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-128
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
  • [31] Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation
    Cabrera, Cristina Calderon
    Falantes, Jose F.
    Gomez, Marina
    Parody, Rocio
    Malaver, Francisco J. Marquez
    Martino, Marla L.
    Gonzalez, Jose
    Montero, Isabel
    Espigado, Ildefonso
    Perez-Simon, Jose Antonio
    [J]. BLOOD, 2013, 122 (21)
  • [32] Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination With Azacitidine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 14 - 16
  • [33] Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes
    Komrokji, Rami S.
    Al Ali, Najla
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew T.
    Lancet, Jeffrey E.
    Sallman, David A.
    [J]. BLOOD, 2021, 138
  • [34] Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Berdeja, Jesus G.
    Abaza, Yasmin
    Jabbour, Elias
    Essell, James
    Lyons, Roger M.
    Ravandi, Farhad
    Maris, Michael
    Heller, Brian
    DeZern, Amy E.
    Babu, Sunil
    Wright, David
    Anz, Bertrand
    Boccia, Ralph
    Komrokji, Rami S.
    Kuriakose, Philip
    Reeves, James
    Sekeres, Mikkael A.
    Kantarjian, Hagop M.
    Ghalie, Richard
    Roboz, Gail J.
    [J]. CANCER, 2017, 123 (06) : 994 - 1002
  • [35] Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Tiu, Ramon V.
    Advani, Anjali S.
    Afable, Manual
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Paquette, Ronald
    Smith, April
    Strozniak, Lori
    List, Alan F.
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2011, 118 (21) : 279 - 279
  • [36] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes (vol 28, pg 2253, 2010)
    Ganetzky, Rebecca
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3098 - 3098
  • [37] Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Jurcic, Joseph G.
    Jacoby, Meagan A.
    Hong, Wan-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Tong, Bo
    Hogdal, Leah
    Kamalakar, Rajesh
    Hutti, Jessica E.
    Kye, Steve
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2020, 136
  • [38] Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine
    Santini, Valeria
    Amato, Cristina
    De Pourcq, Sven
    della Seta, Roberta
    Caciagli, Barbara
    Raddi, Marco Gabriele
    Consagra, Angela
    Rigodanza, Luca
    Mattiuz, Giorgio
    Defina, Marzia
    Galimberti, Sara
    Maestrini, Giacomo
    Sanna, Alessandro
    [J]. BLOOD, 2023, 142
  • [39] Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
    Komrokji, Rami S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S56 - S59
  • [40] Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
    Bazinet, Alexandre
    Desikan, Sai Prasad
    Li, Ziyi
    Rodriguez-Sevilla, Juan Jose
    Venugopal, Sangeetha
    Urrutia, Samuel
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Chien, Kelly S.
    Hammond, Danielle
    Kanagal-Shamanna, Rashmi
    Ganan-Gomez, Irene
    Kadia, Tapan M.
    Borthakur, Gautam
    Dinardo, Courtney D.
    Daver, Naval G.
    Jabbour, Elias J.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1319 - 1326
12345